Trials / Recruiting

RecruitingNCT06409585

Cardiomyopathies and Heart Muscle Diseases: Cardiac Imaging in the Evaluation of Myocardial Fibrosis Transition

Status: Recruiting
Phase: —
Study type: Observational
Enrollment: 290 (estimated)

Sponsor: University of Edinburgh · Academic / Other
Sex: All
Age: 30 Years – 90 Years
Healthy volunteers: Accepted

Summary

Heart scarring, also known as fibrosis, plays a major role in a lot of heart muscle abnormalities. These abnormalities of the heart muscle can lead to major issues such as symptoms of heart failure, dangerous heart rhythm disturbances and even death. However, a lot of these conditions are still not fully understood and treatment options are limited. We here aim to use a new radioactive dye called 68Ga-FAPI to identify patterns and the activity of heart muscle scarring. This radioactive dye is being used in humans particularly in identifying and monitoring cancers and has shown promise in identifying scarring in the heart as well. This will help us not only understand the underlying disease process and risk stratify these patients but also potentially help us develop new targeted therapies that can affect heart muscle scarring. Participants will undergo a baseline MRI scan using this new dye and a plain MRI scan will repeated 12-18 months after to see if there are any changes in the process.

Conditions

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	68Ga-FAPI or 18F-AlF-FAPI cardiac PET-MR	200MBq of the above named radiotracer will be administered for PET-MR
DIAGNOSTIC_TEST	Echocardiogram	Echocardiogram at baseline and 1 year follow-up
DIAGNOSTIC_TEST	Cardiac MRI	Cardiac MRI at 1 year

Timeline

Start date: 2023-05-01
Primary completion: 2027-08-01
Completion: 2028-01-01
First posted: 2024-05-10
Last updated: 2025-08-19

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT06409585. Inclusion in this directory is not an endorsement.